<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Qualitative Research on Psilocybin-Assisted Psychotherapy for the Treatment of Mental Health Disorders: A Scoping Review Protocol</title>
				<funder>
					<orgName type="full">Australian Government Research Training Program Scholarship</orgName>
				</funder>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><forename type="first">Jennifer</forename><surname>Pincombe</surname></persName>
							<email>pincombe-jpincombe@swin.edu.au</email>
							<affiliation key="aff0">
								<orgName type="department">Centre for Mental Health</orgName>
								<orgName type="institution">Swinburne University of Technology</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Martin</forename><surname>Williams</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Centre for Mental Health</orgName>
								<orgName type="institution">Swinburne University of Technology</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Sean</forename><surname>Carruthers</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Centre for Mental Health</orgName>
								<orgName type="institution">Swinburne University of Technology</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Susan</forename><surname>Rossell</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Centre for Mental Health</orgName>
								<orgName type="institution">Swinburne University of Technology</orgName>
							</affiliation>
						</author>
						<title level="a" type="main">Qualitative Research on Psilocybin-Assisted Psychotherapy for the Treatment of Mental Health Disorders: A Scoping Review Protocol</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">15F22D3763D80858AB8EA021DEE265A6</idno>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.8.2" ident="GROBID" when="2025-10-22T21:01+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<label type="revision">a91ee48</label>
					<label type="parameters">startPage=-1, endPage=-1, consolidateCitations=0, consolidateHeader=1, consolidateFunders=0, includeRawAffiliations=false, includeRawCitations=false, includeRawCopyrights=false, generateTeiIds=false, generateTeiCoordinates=[], sentenceSegmentation=false, flavor=null</label>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>Anxiety</term>
					<term>depression</term>
					<term>psilocybin</term>
					<term>psychedelic</term>
					<term>qualitative</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p>There has been a surge in research into psilocybin-assisted psychotherapy over the past decade, with many studies indicating this may be an effective novel intervention for several mental health disorders. Researchers are increasingly incorporating qualitative analysis into their studies in recognition of the rich, contextual information this provides. This scoping review aims to identify the existing qualitative research on psilocybin-assisted psychotherapy for the treatment of mental health disorders, analyse trends in research questions and methods, and recognise opportunities for future qualitative research.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods and Analysis</head><p>The methodological guidelines set out in the JBI Manual for Evidence Synthesis (Aromataris et al., 2024) will be used to conduct the review. The review will include qualitative studies involving psilocybin-assisted psychotherapy, administered in a controlled research setting, for the treatment of any mental health disorder. Microdosing studies will be excluded. PubMed, Scopus, PsycNET, and reference lists of included studies will be searched. Two reviewers will screen papers for inclusion. Data will be extracted into a table and findings will be presented in a narrative form.</p><p>Relevant qualitative research will be identified, trends in the qualitative research questions and methods will be analysed, and opportunities for future qualitative research will be discussed.</p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Background and Rationale</head><p>Studies investigating psilocybin-assisted psychotherapy indicate this may be an effective intervention for a variety of mental health disorders <ref type="bibr" target="#b8">(Castro Santos &amp; Gama Marques, 2021;</ref><ref type="bibr" target="#b17">Irizarry et al., 2022;</ref><ref type="bibr" target="#b18">IsHak et al., 2023)</ref>. Psilocybin is a classic psychedelic that occurs naturally in mushrooms of the Psilocybe and related genera. It is a prodrug of psilocin -a partial agonist of serotonin 5-HT2A/2C and 1A receptors, which elicits altered states of consciousness, including changes in perception, thoughts, and emotions <ref type="bibr" target="#b11">(Griffiths et al., 2016;</ref><ref type="bibr" target="#b14">Halberstadt, 2015)</ref>. Multiple studies have found that administration of a high dose of psilocybin in combination with psychotherapy can have significant therapeutic effects in people with mental health disorders, including depression, obsessive-compulsive disorder, and substance use disorder <ref type="bibr" target="#b8">(Castro Santos &amp; Gama Marques, 2021;</ref><ref type="bibr" target="#b18">IsHak et al., 2023)</ref>. This intervention, termed psilocybin-assisted psychotherapy, typically involves three stages: preparation sessions, to ready the person for the psilocybin experience; treatment sessions, during which the psilocybin is administered in combination with supportive psychotherapy; and post-treatment sessions, whereby the experiences of the treatment sessions are integrated into the person's daily life <ref type="bibr" target="#b16">(Horton et al., 2022)</ref>.</p><p>Psilocybin has been used across the world for thousands of years for cultural, religious, spiritual, healing, and recreational purposes <ref type="bibr" target="#b15">(Heilman, 2022)</ref>. Western academic research into the therapeutic effects of psilocybin began in the late 1950s. However, psychedelic research effectively ceased in the early 1970s, following the passage of the Controlled Substances Act in the United States; countries that were signatories to the International Conventions imposed similar restrictions shortly thereafter. These regulatory restrictions across the world prevented further academic research into psychedelics for the next two decades <ref type="bibr" target="#b15">(Heilman, 2022)</ref>. However, psychedelic research began to revive in the 1990s under strict regulatory conditions <ref type="bibr">(Strassman et al., 1994;</ref><ref type="bibr">Strassman &amp; Qualls, 1994)</ref>, with several landmark studies (e.g. <ref type="bibr" target="#b12">Griffiths et al., 2006)</ref> facilitating further research in this space in the mid-2000s.</p><p>Since then, there has been a proliferation of research into psilocybin-assisted psychotherapy. Multiple systematic reviews and meta-analyses have now been published, reviewing the safety and efficacy of the novel intervention. These reviews have captured studies that have included a variety of mental health conditions, such as depression (e.g., <ref type="bibr" target="#b9">Fang et al., 2024;</ref><ref type="bibr" target="#b13">Haikazian et al., 2023;</ref><ref type="bibr" target="#b24">Metaxa &amp; Clarke, 2024;</ref><ref type="bibr" target="#b32">Watford &amp; Masood, 2024)</ref>, substance use disorder <ref type="bibr" target="#b20">(Kaminski &amp; Reinert, 2023;</ref><ref type="bibr" target="#b31">van der Meer et al., 2023)</ref>, end-of-life anxiety <ref type="bibr" target="#b34">(Yu et al., 2021)</ref> and other mental health disorders <ref type="bibr" target="#b18">(IsHak et al., 2023)</ref>.</p><p>Reflecting the general emphasis on quantitative studies in psychedelic research, there is a relative lack of qualitative research reported in the contemporary literature <ref type="bibr" target="#b6">(Breeksema et al., 2024)</ref>. Qualitative studies are important in evaluating the safety and efficacy of new interventions as they deepen our understanding of participant experiences and outcomes, and provide contextual insights <ref type="bibr" target="#b22">(Levitt et al., 2018)</ref> Qualitative research also has the benefit of not being constrained by set questionnaires that may not capture important features of change or experience. Researchers are increasingly incorporating qualitative analyses into their studies in recognition of the rich information this provides <ref type="bibr" target="#b7">(Breeksema et al., 2020)</ref>. <ref type="bibr" target="#b7">Breeksema et al. (2020)</ref> conducted a systematic review of qualitative studies involving a variety of psychedelic treatments for psychiatric disorders. Of the qualitative studies they identified that involved psilocybin, two studies related to substance use disorder <ref type="bibr" target="#b25">(Nielson et al., 2018;</ref><ref type="bibr" target="#b26">Noorani et al., 2018)</ref>, one study related to end-of-life anxiety, generating two papers <ref type="bibr" target="#b4">(Belser et al., 2017;</ref><ref type="bibr" target="#b30">Swift et al., 2017)</ref>, and one study related to depression <ref type="bibr" target="#b33">(Watts et al., 2017)</ref>. Other qualitative studies on psilocybin-assisted psychotherapy have included participants with depression <ref type="bibr" target="#b0">(Agin-Liebes &amp; Davis, 2022;</ref><ref type="bibr" target="#b6">Breeksema et al., 2024;</ref><ref type="bibr">Kaelen et al., 2018), HIV and</ref><ref type="bibr">trauma (Agin-Liebes et al., 2021)</ref>, cancer-related anxiety and depression <ref type="bibr" target="#b23">(Malone et al., 2018)</ref>, tobacco addiction <ref type="bibr" target="#b10">(Garcia-Romeu et al., 2015;</ref><ref type="bibr" target="#b26">Noorani et al., 2018)</ref>, and alcohol use disorder <ref type="bibr" target="#b2">(Agin-Liebes et al., 2024;</ref><ref type="bibr">Bogenschutz &amp; Ross, 2018;</ref><ref type="bibr" target="#b25">Nielson et al., 2018)</ref>.</p><p>These studies have used a variety of qualitative methodologies and the research questions have focused on a range of aspects of the intervention. Considering the surge in research in this area, it is an appropriate time to review the literature. A preliminary review of the literature indicates a systematic review may be premature, given the small number and heterogenous nature of the qualitative research on psilocybin-assisted psychotherapy. However, a scoping review is appropriate to identify the relevant literature, examine the current trends in research questions and methods, and recognise opportunities for future research.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Objective</head><p>The primary research question for this scoping review is:</p><p>• What qualitative research has been conducted on psilocybin-assisted psychotherapy for the treatment of mental health disorders?</p><p>The secondary research questions for this scoping review are:</p><p>• What are the trends in terms of research questions asked and methods used?</p><p>• What are the opportunities for future qualitative research on psilocybin-assisted psychotherapy for the treatment of mental health disorders?</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods</head><p>This scoping review protocol has been developed according to the guidelines and template provided by <ref type="bibr" target="#b21">(Lely et al., 2023)</ref>. The scoping review will follow the methodology outlined in the JBI Manual for Evidence Synthesis <ref type="bibr">(Aromataris et al., 2024)</ref>. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Extension for Scoping Reviews will be used as the reporting guideline to write the final scoping review manuscript.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Eligibility Criteria</head><p>The eligibility criteria for the scoping review are summarised in Table <ref type="table" target="#tab_0">1</ref>. The review will include studies in which participants are adults (&gt;18 years) who are being treated for any mental health disorder. Included interventions are those that combine at least one dose of psilocybin with psychotherapy in a controlled research setting. The study must include a qualitative analysis of participant data. Acceptable evidence sources are clinical trials, pilot trials, and case reports, where the full text is available in English.</p><p>Studies will be excluded if conducted in healthy adults without a mental health disorder, the intervention does not include dosing with psilocybin, does not have a psychotherapy component, or has been delivered in a setting other than a controlled research setting (e.g., a naturalistic setting). Studies that only involve microdoses of psilocybin will be excluded. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Any other type of source Full text not available in English</head><p>^ A microdose will be defined as follows: &lt;0.5g psilocybe cubensis dried mushroom (oral), &lt;5mg psilocybin synthetic (oral), or &lt; 0.5mg psilocybin synthetic (intravenous) <ref type="bibr" target="#b27">(Polito &amp; Liknaitzky, 2022</ref>).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Information Sources and Search Strategy</head><p>The search strategy will be developed, and peer reviewed within the research team. The databases PubMed and Scopus will be searched, and the reference lists of included studies will be manually searched for additional studies. Search terms will pair key words associated with the intervention (e.g., psilocybin) and methodology (e.g., qualitative). Search terms for the population will not be included to allow for broad coverage of mental health conditions. The full list of search terms is provided in Supplementary Materials Table <ref type="table" target="#tab_0">1</ref>. All citations will be uploaded to Zotero for reference management and deduplication.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study Selection</head><p>After duplicates have been removed, all citations will be exported into Microsoft Excel for study screening and selection. Two independent reviewers will screen and select the studies and interrater reliability will be assessed at the abstract screening stage. All disagreements will be discussed with a third reviewer until resolved. In the first stage of screening, potentially eligible and ineligible studies will be identified by reviewing the titles and abstracts and assessing these against the inclusion/exclusion criteria. In the second stage of screening, the full text of potentially eligible studies will be assessed against the inclusion/exclusion criteria.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Data Extraction</head><p>One reviewer will independently extract the data from the included papers into a tool created by the research team (see draft at Table <ref type="table" target="#tab_1">2</ref>). The extracted data will include information about the author(s), year and type of publication, study design, population, and research questions. The data extraction tool will be updated and refined as required. The completed tool will be peer reviewed by a second reviewer. Analysis method E.g. thematic analysis, interpretative phenomenological analysis</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>IPA</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Synthesis and presentation of results</head><p>Data will be cleaned and synthesised by one reviewer in Microsoft Excel. The process to identify, select and exclude studies will be visualised in a PRISMA flow diagram. The findings will be presented in a narrative form, addressing the review objective and questions. A summary of the key findings and extracted data will be provided in a table. The approach to synthesising and presenting results may change as the review process progresses.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Ethics and dissemination</head><p>This scoping review will synthesise information from published and publicly available literature. As such, ethics approval will not be required to conduct this scoping review. An article reporting the results of the scoping review will be submitted for publication in a peer-reviewed journal.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusion</head><p>This scoping review will deliver a comprehensive overview of the qualitative research on psilocybin-assisted psychotherapy for the treatment of mental health disorders. It will also identify gaps in the literature. The information disseminated in this review may help inform the design of future qualitative research into this subject.</p></div><figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1</head><label>1</label><figDesc>Summary of Eligibility Criteria for Scoping Review</figDesc><table><row><cell></cell><cell>Inclusion criteria</cell><cell>Exclusion criteria</cell></row><row><cell>Population</cell><cell>Adults (&gt; 18 years) who are being treated for</cell><cell>Healthy participants</cell></row><row><cell></cell><cell>a mental health disorder</cell><cell>Participants without a mental</cell></row><row><cell></cell><cell></cell><cell>health disorder</cell></row><row><cell></cell><cell></cell><cell>Age &lt; 18 years</cell></row><row><cell>Intervention</cell><cell>Psilocybin-Assisted Psychotherapy -i.e., the combination of psychotherapy with at</cell><cell>Psilocybin dose without psychotherapy</cell></row><row><cell></cell><cell>least one psilocybin dosing session.</cell><cell>Microdosing ^ of psilocybin</cell></row><row><cell></cell><cell></cell><cell>Non-psilocybin-based</cell></row><row><cell></cell><cell></cell><cell>psychedelic assisted</cell></row><row><cell></cell><cell></cell><cell>psychotherapy</cell></row><row><cell>Context/Setting</cell><cell>Controlled research setting</cell><cell>Any other setting</cell></row><row><cell>Outcomes</cell><cell>Includes qualitative analyses of participant</cell><cell>Does not include qualitative</cell></row><row><cell></cell><cell>outcomes, experiences, or perspectives</cell><cell>analyses</cell></row><row><cell>Types of Evidence</cell><cell>Clinical trials</cell><cell></cell></row><row><cell>Sources</cell><cell>Pilot studies</cell><cell></cell></row><row><cell></cell><cell>Case reports Full text available in English</cell><cell></cell></row><row><cell></cell><cell>Peer reviewed</cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 2</head><label>2</label><figDesc>Draft data extraction form</figDesc><table><row><cell></cell><cell>Guidance</cell><cell>Example</cell></row><row><cell>Author</cell><cell>E.g., Smith; Smith &amp; Hunt;</cell><cell>Belser et al.</cell></row><row><cell></cell><cell>Smith et al. (for more than 2</cell><cell></cell></row><row><cell></cell><cell>authors)</cell><cell></cell></row><row><cell>Title of source</cell><cell>Full title of the article</cell><cell>Patient Experiences of Psilocybin-Assisted Psychotherapy: An Interpretative</cell></row><row><cell></cell><cell></cell><cell>Phenomenological Analysis</cell></row><row><cell>Publication</cell><cell>Journal name</cell><cell>Journal of Humanistic Psychology</cell></row><row><cell>Year</cell><cell cols="2">Year the article was published 2017</cell></row><row><cell>Country</cell><cell>Country in which the study took place</cell><cell>USA</cell></row><row><cell>Study design</cell><cell>E.g., Clinical Trial, pilot trial,</cell><cell>Quantitative double-blind, crossover,</cell></row><row><cell></cell><cell>case report</cell><cell>placebo-controlled pilot study</cell></row><row><cell>Study context</cell><cell>Note whether the participants are part of a broader</cell><cell>Participants had previously been enrolled in a Phase II clinical trial</cell></row><row><cell></cell><cell>study/clinical trial</cell><cell></cell></row><row><cell>Sample size</cell><cell>Total sample size</cell><cell>13</cell></row><row><cell>Age (years)</cell><cell>Age range and mean</cell><cell>18 -76 years (M = 50 years)</cell></row><row><cell>Gender</cell><cell>Frequency of participant genders</cell><cell>Missing</cell></row><row><cell>Mental health</cell><cell>E.g., Depression, anxiety,</cell><cell>Projected life expectancy of at least 1 year,</cell></row><row><cell>disorder(s) of</cell><cell>anorexia</cell><cell>and a primary diagnosis of acute stress</cell></row><row><cell>participants</cell><cell></cell><cell>disorder, generalized anxiety disorder, anxiety disorder due to cancer, or adjustment disorder</cell></row><row><cell></cell><cell></cell><cell>with anxiety</cell></row><row><cell>Research</cell><cell cols="2">Qualitative research questions We address research questions regarding the</cell></row><row><cell>question(s)</cell><cell></cell><cell>form and content of participant experiences</cell></row><row><cell></cell><cell></cell><cell>during the psilocybin dosage sessions, descriptions of their subjective experiences of</cell></row><row><cell></cell><cell></cell><cell>this psychological intervention in context, and</cell></row><row><cell></cell><cell></cell><cell>their understandings of the embedded</cell></row><row><cell></cell><cell></cell><cell>meanings of their lived experiences</cell></row><row><cell>Intervention details</cell><cell>Include dosage of psilocybin and course of psychotherapy. E.g. 25 mg; 2 preparatory sessions,</cell><cell>Two drug administration sessions, separated by 7 weeks, a total of nine sessions of adjunctive psychotherapy with two licensed</cell></row><row><cell></cell><cell>dosing session; 1 integration</cell><cell>psychotherapists conducted before, between,</cell></row><row><cell></cell><cell>session.</cell><cell>and after the two 8-hour drug administration</cell></row><row><cell></cell><cell></cell><cell>sessions, and 6 months of follow-up</cell></row></table></figure>
		</body>
		<back>

			<div type="funding">
<div><head>Funding</head><p>The primary author has been supported through an <rs type="funder">Australian Government Research Training Program Scholarship</rs>. No other funding will be received to conduct this scoping review.</p></div>
			</div>
			<listOrg type="funding">
			</listOrg>
			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conflict of interest</head><p>The authors involved in this scoping review do not have a conflict of interest to declare.</p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Psilocybin for the Treatment of Depression: A Promising New Pharmacotherapy Approach</title>
		<author>
			<persName><forename type="first">G</forename><surname>Agin-Liebes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename><surname>Davis</surname></persName>
		</author>
		<idno type="DOI">10.1007/7854_2021_282</idno>
		<ptr target="https://doi.org/10.1007/7854_2021_282" />
	</analytic>
	<monogr>
		<title level="j">Current Topics in Behavioral Neurosciences</title>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="issue">101535383</biblScope>
			<biblScope unit="page" from="125" to="140" />
			<date type="published" when="2022">2022. &lt;2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Participant Reports of Mindfulness, Posttraumatic Growth, and Social Connectedness in Psilocybin-Assisted Group Therapy: An Interpretive Phenomenological Analysis</title>
		<author>
			<persName><forename type="first">G</forename><surname>Agin-Liebes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Ekman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Anderson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Malloy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Haas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Woolley</surname></persName>
		</author>
		<idno type="DOI">10.1177/00221678211022949</idno>
		<ptr target="https://doi.org/10.1177/00221678211022949" />
	</analytic>
	<monogr>
		<title level="j">Journal of Humanistic Psychology</title>
		<imprint>
			<biblScope unit="page">00221678211022949</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Reports of self-compassion and affect regulation in psilocybinassisted therapy for alcohol use disorder: An interpretive phenomenological analysis</title>
		<author>
			<persName><forename type="first">G</forename><surname>Agin-Liebes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Nielson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Zingman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Haas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">T</forename><surname>Owens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Rogers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bogenschutz</surname></persName>
		</author>
		<idno type="DOI">10.1037/adb0000935</idno>
		<ptr target="https://doi.org/10.1037/adb0000935" />
	</analytic>
	<monogr>
		<title level="j">Psychology of Addictive Behaviors</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="101" to="113" />
			<date type="published" when="2024">2024</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">JBI Manual for Evidence Synthesis</title>
		<idno type="DOI">10.46658/JBIMES-24-01</idno>
		<ptr target="https://doi.org/10.46658/JBIMES-24-01" />
	</analytic>
	<monogr>
		<title level="j">JBI</title>
		<editor>
			<persName><forename type="first">E</forename><surname>Aromataris</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">C</forename><surname>Lockwood</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">K</forename><surname>Porritt</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">B</forename><surname>Pilla</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">Z</forename><surname>Jordan</surname></persName>
		</editor>
		<imprint>
			<date type="published" when="2024">2024</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Patient Experiences of Psilocybin-Assisted Psychotherapy: An Interpretative Phenomenological Analysis</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">B</forename><surname>Belser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Agin-Liebes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">C</forename><surname>Swift</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Terrana</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Devenot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">L</forename><surname>Friedman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Guss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bossis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ross</surname></persName>
		</author>
		<idno type="DOI">10.1177/0022167817706884</idno>
		<ptr target="https://doi.org/10.1177/0022167817706884" />
	</analytic>
	<monogr>
		<title level="j">Journal of Humanistic Psychology</title>
		<imprint>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="354" to="388" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Therapeutic applications of classic hallucinogens</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Bogenschutz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ross</surname></persName>
		</author>
		<idno type="DOI">10.1007/7854_2016_464</idno>
		<ptr target="https://doi.org/10.1007/7854_2016_464" />
	</analytic>
	<monogr>
		<title level="j">Current Topics in Behavioral Neurosciences</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="361" to="391" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Patient perspectives and experiences with psilocybin treatment for treatment-resistant depression: A qualitative study</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Breeksema</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Niemeijer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Krediet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Karsten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Kamphuis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Vermetten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Van Den Brink</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Schoevers</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41598-024-53188-9</idno>
		<ptr target="https://doi.org/10.1038/s41598-024-53188-9" />
	</analytic>
	<monogr>
		<title level="j">Scientific Reports</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="issue">1</biblScope>
			<date type="published" when="2024">2024. 2929</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Psychedelic Treatments for Psychiatric Disorders: A Systematic Review and Thematic Synthesis of Patient Experiences in Qualitative Studies</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Breeksema</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Niemeijer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Krediet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Vermetten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Schoevers</surname></persName>
		</author>
		<idno type="DOI">10.1007/s40263-020-00748-y</idno>
		<ptr target="https://doi.org/10.1007/s40263-020-00748-y" />
	</analytic>
	<monogr>
		<title level="j">CNS Drugs</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="925" to="946" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">What is the clinical evidence on psilocybin for the treatment of psychiatric disorders? A systematic review</title>
		<author>
			<persName><forename type="first">H</forename><surname>Castro Santos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Gama Marques</surname></persName>
		</author>
		<idno type="DOI">10.1097/j.pbj.0000000000000128</idno>
		<ptr target="https://doi.org/10.1097/j.pbj.0000000000000128" />
	</analytic>
	<monogr>
		<title level="j">Porto Biomedical Journal</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">128</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Efficacy and acceptability of psilocybin for primary or secondary depression: A systematic review and meta-analysis of randomized controlled trials</title>
		<author>
			<persName><forename type="first">S</forename><surname>Fang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Zhang</surname></persName>
		</author>
		<idno type="DOI">10.3389/fpsyt.2024.1359088</idno>
		<ptr target="https://doi.org/10.3389/fpsyt.2024.1359088" />
	</analytic>
	<monogr>
		<title level="j">Frontiers in Psychiatry</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page">1359088</biblScope>
			<date type="published" when="2024">2024</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Psilocybin-occasioned Mystical Experiences in the Treatment of Tobacco Addiction</title>
		<author>
			<persName><forename type="first">A</forename><surname>Garcia-Romeu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">R</forename><surname>Griffiths</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">W</forename><surname>Johnson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Current Drug Abuse Reviews</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="157" to="164" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">R</forename><surname>Griffiths</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">W</forename><surname>Johnson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Carducci</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Umbricht</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">A</forename><surname>Richards</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">D</forename><surname>Richards</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Cosimano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Klinedinst</surname></persName>
		</author>
		<idno type="DOI">10.1177/0269881116675513</idno>
		<ptr target="https://doi.org/10.1177/0269881116675513" />
	</analytic>
	<monogr>
		<title level="j">Journal of Psychopharmacology</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="1181" to="1197" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Psilocybin can occasion mysticaltype experiences having substantial and sustained personal meaning and spiritual significance</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">R</forename><surname>Griffiths</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">A</forename><surname>Richards</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Mccann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Jesse</surname></persName>
		</author>
		<idno type="DOI">10.1007/s00213-006-0457-5</idno>
		<ptr target="https://doi.org/10.1007/s00213-006-0457-5" />
	</analytic>
	<monogr>
		<title level="j">Psychopharmacology</title>
		<imprint>
			<biblScope unit="volume">187</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="268" to="283" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Psilocybin-assisted therapy for depression: A systematic review and meta-analysis</title>
		<author>
			<persName><forename type="first">S</forename><surname>Haikazian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C J</forename><surname>Chen-Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Johnson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Fancy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Levinta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">I</forename><surname>Husain</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Mansur</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Mcintyre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Rosenblat</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.psychres.2023.115531</idno>
		<ptr target="https://doi.org/10.1016/j.psychres.2023.115531" />
	</analytic>
	<monogr>
		<title level="j">Psychiatry Research</title>
		<imprint>
			<biblScope unit="volume">329</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Recent advances in the neuropsychopharmacology of serotonergic hallucinogens</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Halberstadt</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.bbr.2014.07.016</idno>
		<ptr target="https://doi.org/10.1016/j.bbr.2014.07.016" />
	</analytic>
	<monogr>
		<title level="j">Behavioural Brain Research</title>
		<imprint>
			<biblScope unit="volume">277</biblScope>
			<biblScope unit="page" from="99" to="120" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">The History, Legalization, and Potentials of Psilocybin-Assisted Psychotherapy</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Heilman</surname></persName>
		</author>
		<idno type="DOI">10.31275/20222633</idno>
		<ptr target="https://doi.org/10.31275/20222633" />
	</analytic>
	<monogr>
		<title level="j">Journal of Scientific Exploration</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="623" to="640" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Systematized Review of Psychotherapeutic Components of Psilocybin-Assisted Psychotherapy</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Horton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Morrison</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Schmidt</surname></persName>
		</author>
		<idno type="DOI">10.1176/appi.psychotherapy.20220012</idno>
		<ptr target="https://doi.org/10.1176/appi.psychotherapy.20220012" />
	</analytic>
	<monogr>
		<title level="j">American Journal of Psychotherapy</title>
		<imprint>
			<biblScope unit="volume">75</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="140" to="149" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Psilocybin as a Treatment for Psychiatric Illness: A Meta-Analysis</title>
		<author>
			<persName><forename type="first">R</forename><surname>Irizarry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Winczura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Dimassi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Dhillon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Minhas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Larice</surname></persName>
		</author>
		<idno type="DOI">10.7759/cureus.31796</idno>
		<ptr target="https://doi.org/10.7759/cureus.31796" />
	</analytic>
	<monogr>
		<title level="j">Cureus</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page">31796</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">The impact of psilocybin on patients experiencing psychiatric symptoms: A systematic review of randomized clinical trials</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">W</forename><surname>Ishak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Garcia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Pearl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Dang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>William</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Totlani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Danovitch</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Innovations in Clinical Neuroscience</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="issue">4-6</biblScope>
			<biblScope unit="page" from="39" to="48" />
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">The hidden therapist: Evidence for a central role of music in psychedelic therapy</title>
		<author>
			<persName><forename type="first">M</forename><surname>Kaelen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Giribaldi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Raine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Evans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Timmermann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Rodriguez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Roseman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Feilding</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Nutt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Carhart-Harris</surname></persName>
		</author>
		<idno type="DOI">10.1007/s00213-017-4820-5</idno>
		<ptr target="https://doi.org/10.1007/s00213-017-4820-5" />
	</analytic>
	<monogr>
		<title level="j">Psychopharmacology</title>
		<imprint>
			<biblScope unit="volume">235</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="505" to="519" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">The Tolerability and Safety of Psilocybin in Psychiatric and Substance-Dependence Conditions: A Systematic Review</title>
		<author>
			<persName><forename type="first">D</forename><surname>Kaminski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Reinert</surname></persName>
		</author>
		<idno type="DOI">10.1177/10600280231205645</idno>
		<ptr target="https://doi.org/10.1177/10600280231205645" />
	</analytic>
	<monogr>
		<title level="j">Annals of Pharmacotherapy</title>
		<imprint>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<monogr>
		<title level="m" type="main">How to write a scoping review protocol: Guidance and template</title>
		<author>
			<persName><forename type="first">J</forename><surname>Lely</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">C</forename><surname>Morris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Sasson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">D</forename><surname>Camarillo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Livinski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Butera</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wickstrom</surname></persName>
		</author>
		<idno type="DOI">10.17605/OSF.IO/YM65X</idno>
		<ptr target="https://doi.org/10.17605/OSF.IO/YM65X" />
		<imprint>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Journal article reporting standards for qualitative primary, qualitative meta-analytic, and mixed methods research in psychology: The APA Publications and Communications Board task force report</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Levitt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bamberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Creswell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Frost</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Josselson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Suárez-Orozco</surname></persName>
		</author>
		<idno type="DOI">10.1037/amp0000151</idno>
		<ptr target="https://doi.org/10.1037/amp0000151" />
	</analytic>
	<monogr>
		<title level="j">American Psychologist</title>
		<imprint>
			<biblScope unit="volume">73</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="26" to="46" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Individual Experiences in Four Cancer Patients Following Psilocybin-Assisted Psychotherapy</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">C</forename><surname>Malone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Mennenga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Guss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">K</forename><surname>Podrebarac</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">T</forename><surname>Owens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">P</forename><surname>Bossis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">B</forename><surname>Belser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Agin-Liebes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Bogenschutz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ross</surname></persName>
		</author>
		<idno type="DOI">10.3389/fphar.2018.00256</idno>
		<idno>MEDLINE &lt;2017 to 2019</idno>
		<ptr target="https://doi.org/10.3389/fphar.2018.00256" />
	</analytic>
	<monogr>
		<title level="j">Frontiers in Pharmacology</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="issue">101548923</biblScope>
			<biblScope unit="page">256</biblScope>
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Efficacy of psilocybin for treating symptoms of depression: Systematic review and meta-analysis</title>
		<author>
			<persName><forename type="first">A.-M</forename><surname>Metaxa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Clarke</surname></persName>
		</author>
		<idno type="DOI">10.1136/bmj-2023-078084</idno>
		<ptr target="https://doi.org/10.1136/bmj-2023-078084" />
	</analytic>
	<monogr>
		<title level="j">The BMJ</title>
		<imprint>
			<biblScope unit="volume">385</biblScope>
			<biblScope unit="page">78084</biblScope>
			<date type="published" when="2024">2024</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">The Psychedelic Debriefing in Alcohol Dependence Treatment: Illustrating Key Change Phenomena through Qualitative Content Analysis of Clinical Sessions</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Nielson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>May</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Forcehimes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Bogenschutz</surname></persName>
		</author>
		<idno type="DOI">10.3389/fphar.2018.00132</idno>
		<ptr target="https://doi.org/10.3389/fphar.2018.00132" />
	</analytic>
	<monogr>
		<title level="j">Frontiers in Pharmacology</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page">132</biblScope>
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Psychedelic therapy for smoking cessation: Qualitative analysis of participant accounts</title>
		<author>
			<persName><forename type="first">T</forename><surname>Noorani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Garcia-Romeu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">C</forename><surname>Swift</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">R</forename><surname>Griffiths</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">W</forename><surname>Johnson</surname></persName>
		</author>
		<idno type="DOI">10.1177/0269881118780612</idno>
		<ptr target="https://doi.org/10.1177/0269881118780612" />
	</analytic>
	<monogr>
		<title level="j">Journal of Psychopharmacology</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="756" to="769" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">The emerging science of microdosing: A systematic review of research on low dose psychedelics (1955-2021) and recommendations for the field</title>
		<author>
			<persName><forename type="first">V</forename><surname>Polito</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Liknaitzky</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.neubiorev.2022.104706</idno>
		<ptr target="https://doi.org/10.1016/j.neubiorev.2022.104706" />
	</analytic>
	<monogr>
		<title level="j">Neuroscience and Biobehavioral Reviews</title>
		<imprint>
			<biblScope unit="volume">139</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Dose-response study of N,N-dimethyltryptamine in humans. I. Neuroendocrine, autonomic, and cardiovascular effects</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Strassman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Qualls</surname></persName>
		</author>
		<idno type="DOI">10.1001/archpsyc.1994.03950020009001</idno>
		<ptr target="https://doi.org/10.1001/archpsyc.1994.03950020009001" />
	</analytic>
	<monogr>
		<title level="j">Archives of General Psychiatry</title>
		<imprint>
			<biblScope unit="volume">51</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="85" to="97" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Dose-response study of N,Ndimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Strassman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Qualls</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">H</forename><surname>Uhlenhuth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Kellner</surname></persName>
		</author>
		<idno type="DOI">10.1001/archpsyc.1994.03950020022002</idno>
		<ptr target="https://doi.org/10.1001/archpsyc.1994.03950020022002" />
	</analytic>
	<monogr>
		<title level="j">Archives of General Psychiatry</title>
		<imprint>
			<biblScope unit="volume">51</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="98" to="108" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Cancer at the dinner table: Experiences of psilocybin-assisted psychotherapy for the treatment of cancer-related distress</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">C</forename><surname>Swift</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">B</forename><surname>Belser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Agin-Liebes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Devenot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Terrana</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">L</forename><surname>Friedman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Guss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">P</forename><surname>Bossis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ross</surname></persName>
		</author>
		<idno type="DOI">10.1177/0022167817715966</idno>
		<ptr target="https://doi.org/10.1177/0022167817715966" />
	</analytic>
	<monogr>
		<title level="j">Journal of Humanistic Psychology</title>
		<imprint>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="488" to="519" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Therapeutic effect of psilocybin in addiction: A systematic review</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">B</forename><surname>Van Der Meer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Fuentes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Kaptein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Schoones</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>De Waal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">E</forename><surname>Goudriaan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Kramers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Schellekens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Somers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Bossong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Batalla</surname></persName>
		</author>
		<idno type="DOI">10.3389/fpsyt.2023.1134454</idno>
		<ptr target="https://doi.org/10.3389/fpsyt.2023.1134454" />
	</analytic>
	<monogr>
		<title level="j">Frontiers in Psychiatry</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page">1134454</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Psilocybin, an Effective Treatment for Major Depressive Disorder in Adults-A Systematic Review</title>
		<author>
			<persName><forename type="first">T</forename><surname>Watford</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Masood</surname></persName>
		</author>
		<idno type="DOI">10.9758/cpn.23.1120</idno>
		<ptr target="https://doi.org/10.9758/cpn.23.1120" />
	</analytic>
	<monogr>
		<title level="j">Clinical Psychopharmacology and Neuroscience</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="2" to="12" />
			<date type="published" when="2024">2024</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Patients&apos; accounts of increased &quot;connectedness&quot; and &quot;acceptance&quot; after psilocybin for treatment-resistant depression</title>
		<author>
			<persName><forename type="first">R</forename><surname>Watts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Day</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Krzanowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Nutt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Carhart-Harris</surname></persName>
		</author>
		<idno type="DOI">10.1177/0022167817709585</idno>
		<ptr target="https://doi.org/10.1177/0022167817709585" />
	</analytic>
	<monogr>
		<title level="j">Journal of Humanistic Psychology</title>
		<imprint>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="520" to="564" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Psilocybin for end-of-life anxiety symptoms: A systematic review and metaanalysis</title>
		<author>
			<persName><forename type="first">C.-L</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F.-C</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S.-N</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P.-T</forename><surname>Tseng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Stubbs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T.-C</forename><surname>Yeh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C.-W</forename><surname>Hsu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D.-J</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C.-S</forename><surname>Liang</surname></persName>
		</author>
		<idno type="DOI">10.30773/pi.2021.0209</idno>
		<ptr target="https://doi.org/10.30773/pi.2021.0209" />
	</analytic>
	<monogr>
		<title level="j">Psychiatry Investigation</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="958" to="967" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
